Command Palette

Search for a command to run...

Preprint WatchModerateSeptember 4th, 2026

Microbial valerate is associated with CAR T dysbiosis and its supplementation enhances CAR T function in B-cell lymphoma

Rehman, L.; Song, W.; Rehman, A.; Singh, K.; Rawat, S. G.; Darbaniyan, F.; Le, C. C.; Aletti, F. M.; Weng, J.; Liu, J.; Cheng, X.; Tang, Y.; Patchva, S.; Richard, M. D.; Chu, F.; Cao, J.; Flowers, C. R.; Shpall, E. J.; Tanner, M. R.; Fahrmann, J.; Elinav, E.; Stein-Thoeringer, C. K.; Jain, M. D.; Jenq, R. R.; Jain, A.; Neelapu, S. S.; Zheng, Y.; Saini, N. Y.

Gut microbial valerate depletion defines a dysbiotic state associated with inferior outcomes after CD19 CAR T-cell therapy, and valerate supplementation enhances CAR T-cell function, implying host metabolite state is a modifiable determinant of CD19 CAR-T product efficacy.

Moderate contradiction

2 prior failures

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

This preprint reports that low stool valerate at the time of CAR-T eligibility marks a dysbiotic gut state, and that valerate supplementation improves CD19 CAR-T cell function in B-cell lymphoma models. The mechanistic claim is that host microbial metabolites set the fitness of the CAR-T product itself rather than acting only on the tumor microenvironment. Claidex holds two terminated CD19 programmes, and neither failed for reasons this work would predict. In ly3541860-cd19-rheumatoid-arthritis-phase2a-efficacy-failure an anti-CD19 antibody missed its efficacy endpoint in rheumatoid arthritis, a setting where no engineered cell product was infused and product fitness was not the variable under test. In kyv-101-cd19-car-t-refractory-lupus-nephritis-kysa-1-strategic-reprioritization a CD19 CAR-T programme in lupus nephritis stopped for portfolio reasons before an efficacy readout, so it cannot corroborate or contradict a product-fitness hypothesis either. The flag is therefore raised on target overlap rather than on a direct contradiction. What the preprint does supply is a candidate covariate that CD19 cell-therapy trials have not routinely captured, and the actionable question for future CD19 programmes is whether baseline microbiome state should be measured and reported alongside product characteristics, so that a null efficacy result can be separated from a manufacturing or host-fitness confound. Neither prior failure recorded such data.

Abstract excerpt

Anaerobe-depleting antibiotic exposure is associated with inferior progression-free survival after CD19 CAR T-cell therapy in large B-cell lymphoma, yet the cellular mechanisms linking gut dysbiosis to the CAR T-cell product and whether this imprint is reversible have remained undefined. In two independent CAR-T candidate cohorts, low stool valerate at the time of CAR-T eligibility identified a multi-metabolite-deficient dysbiotic gut microbiome state marked by depletion of fiber-fermenting commensals and loss of carbohydrate-fermentation, SCFA-biosynthesis, and amino-acid metabolism pathways. Reanalysis of single-cell RNA sequencing from 42 lymphoma patients stratified by piperacillin-tazobactam/imipenem/meropenem (PIM) exposure revealed that PIM-exposed CAR T-cell products were CD4-skewed, with significantly elevated AP-1/immediate-early gene (IEG) and cellular activation signatures that together predicted inferior progression-free survival. Ex vivo conditioning of CAR T-cells with valerate produced a chromatin and transcription factor program distinct from butyrate or propionate, characterized by KLF/SP/EGR family engagement, KLF4 promoter opening, and broad induction of AP-1/IEG and MHC class II transcripts, whereas butyrate drove broader chromatin remodeling with TBX21/EOMES/NF-{kappa}B gains and KLF2 promoter closure, and propionate induced an NFY-centered program with preferential commitment to low-mitochondrial-content states. Untargeted metabolomics confirmed valerate uptake and mitochondrial {beta}-oxidation in CAR T-cells, while dietary sodium valerate supplementation in meropenem-treated mice bearing A20 lymphoma significantly reduced tumor burden and extended survival compared with CAR T-cells alone. These findings identify stool valerate as a bedside-deployable biomarker of dysbiosis-imprinted CAR T-cell dysfunction and support ex vivo or dietary valerate supplementation as a clinically tractable strategy to improve CAR-T anti-tumor function in patients with disrupted gut microbiomes.

Matching Claidex post-mortems

2 of 2 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.